Assenagon Asset Management S.A. Reduces Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Assenagon Asset Management S.A. lessened its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 41.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 112,672 shares of the biotechnology company’s stock after selling 80,184 shares during the quarter. Assenagon Asset Management S.A. owned 0.53% of Enanta Pharmaceuticals worth $622,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its stake in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after buying an additional 2,274 shares during the period. GAMMA Investing LLC purchased a new position in Enanta Pharmaceuticals during the first quarter worth about $40,000. Intech Investment Management LLC purchased a new position in Enanta Pharmaceuticals during the fourth quarter worth about $58,000. Squarepoint Ops LLC purchased a new position in Enanta Pharmaceuticals during the fourth quarter worth about $66,000. Finally, Velan Capital Investment Management LP purchased a new position in Enanta Pharmaceuticals during the fourth quarter worth about $75,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. JMP Securities increased their target price on shares of Enanta Pharmaceuticals from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 3rd. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. Two investment analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $7.23 on Thursday. The stock has a market capitalization of $154.58 million, a PE ratio of -1.59 and a beta of 0.76. Enanta Pharmaceuticals, Inc. has a 1 year low of $4.09 and a 1 year high of $17.24. The company’s 50-day simple moving average is $5.97 and its 200-day simple moving average is $6.11.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 79.83% and a negative net margin of 149.57%. On average, sell-side analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.